SkinMedica TNS Recovery Complex 1 fl oz white pump bottle with rose-gold cap
Promising for Aging
What makes this different

It is the product that invented the category: ninety-four percent human fibroblast conditioned medium, the growth-factor, cytokine and matrix-protein secretions of cultured skin cells, sold as a serum since 1999 with a founder's biopsy study behind it and now marketed on the exosomes those same secretions contain. Every growth-factor and exosome serum since is a descendant, and none has a longer clinical or commercial record.

SkinMedica

SkinMedica TNS Recovery Complex Review

The Original Growth Factor Serum Serums serum dermatologist developed Paraben free Fungal-acne safe Not cruelty free

The serum that invented growth-factor skincare, ninety-four percent human fibroblast conditioned medium with a founder's biopsy study and twenty-seven years of loyal use behind it, now relabelled around the exosomes it has always contained. It smooths texture and softens fine lines modestly over three months and helps treated skin settle; it smells of the culture it came from, carries six fragrance allergens it did not need, and costs two hundred and thirty dollars an ounce, which no amount of history makes cheap.

Price $230.00 1 fl oz / 30 mL · more sizes
Shopper rating 4.6 ★★★★★ 490 reviews
On the market 1999 Made in United States
Buy at Amazon ♥
Verdicts

How well it fits each concern

One verdict per concern. Open a row for the reasoning; the receipt has every source.

The scaleRecommendedGoodSupportingEarly evidenceNot for thisAvoidhow it works

Promisingfor AgingGrowth Factors (EGF) has trial-level evidence for aging but no guideline or regulatory standing yet — promising, short of a recommendation; the other actives here are not yet assessed for it.Receipt1 source on the row · 94% declared · row checked Jul 17, 2026 · rule R9p, same reading on 4,872 products · open the receipt

The case for it

  1. Human Fibroblast Conditioned Media has at least one trial behind it for this concern but no guideline or regulatory standing yet.
  2. It is present at an effective concentration, declared or high in the ingredient list.
  3. The formula carries no trigger this concern is sensitive to, with the cautions noted.

Moderate evidenceStandard tolerabilityNo reviews read yet

What would change this: Guideline or regulatory standing for the active on this concern would move this from a promising bet to a recommendation.

Same rule for everyone. “Promising” is the verdict on 4,872 of 45,446 concern verdicts across the catalog; rule R9p decided 4,872 of them. Unchanged since September 25, 2026, engine 5.2.0.

Brand or formulator? Disclose a concentration or correct a fact →

The full receipt: rule, row, sources, dates →All aging products →

Unprovenfor DullnessGlycerin has early or mechanistic evidence for dullness — a reasonable bet, not a recommendation; the other actives here are not yet assessed for it.Receipt1 source on the row · concentration not declared; studied range 2–20% · row checked Jul 17, 2026 · rule R9, same reading on 4,156 products · open the receipt

The case for it

  1. Glycerin has early or mechanistic evidence for this concern, not trial-backed standing.
  2. It is plausibly present at a working level, though the concentration is not declared.
  3. The formula carries no trigger this concern is sensitive to, with the cautions noted.

Limited evidenceStandard tolerabilityNo reviews read yet

What would change this: A declared concentration would move this to a firmer reading of the dose.

Same rule for everyone. “Unproven” is the verdict on 4,156 of 45,446 concern verdicts across the catalog; rule R9 decided 4,156 of them. Unchanged since October 9, 2026, engine 5.2.0.

Brand or formulator? Disclose a concentration or correct a fact →

The full receipt: rule, row, sources, dates →All dullness products →How dullness is treated →

Avoidfor Post-ProcedureThis formula carries fragrance — a known trigger for post procedure — so it is not a fit however good its actives are.Receiptread from the ingredient list: fragrance · rule R1, same reading on 1,307 products · open the receipt

The case for it

  1. Human Fibroblast Conditioned Media has no evidence row yet for this concern — it is in the research queue.
  2. The formula carries a known trigger for this concern, which decides the verdict before any efficacy question.

Not from a trial rowCarries a triggerNo reviews read yet

What would change this: Removing the trigger named above would let the actives be judged on their own.

Same rule for everyone. “Avoid” is the verdict on 1,912 of 45,446 concern verdicts across the catalog; rule R1 decided 1,307 of them. Unchanged since September 25, 2026, engine 5.2.0.

Brand or formulator? Disclose a concentration or correct a fact →

The full receipt: rule, row, sources, dates →All post-procedure products →

Also listed for Sun Damage and Rough Texture — the actives here (Growth Factors (EGF) are in our research queue for those concerns; there is no verdict until their evidence rows are written. That is a gap in our table, not a mark against the product.

Where our review and the verdict differ. The review below was written on the formulation and the published trials; the verdicts above apply the stricter standing test in our methodology — an active earns a recommendation only with guideline or regulatory standing for the concern. Where the two disagree, the verdict is Dermington’s position.

A verdict is Dermington’s assessment of how well a product’s ingredients fit a concern — never a claim about what the product treats. Evidence dots and collected reviews sit beside it and are never blended in. Rules 0.5.1 · evidence table ev-2026.10-r231 · engine 5.2.0 · how we decide · this product’s receipt

Reader poll · Town SquareQuestion 1 of up to 3

Have you used TNS Recovery Complex?

One tap counts. A couple of optional follow-ups come next.

No account neededOne answer each, change it any timeCounted only in anonymous totalsHow the Square counts →
Assessment

Pros & cons

What it does well 7

  • Ninety-four percent human fibroblast conditioned medium, the original growth-factor serum
  • Founder's 2003 pilot study found new collagen and a thicker epidermis on biopsy
  • Twenty-seven years of dermatology-office dispensing and hundreds of loyal reviews
  • Modest but consistent smoothing of texture and fine lines by twelve weeks
  • Helps post-laser and post-peel redness settle faster
  • Airless pump protects the protein content and doses precisely
  • Layers under vitamin C, retinoids and moisturisers without conflict

Where it falls short 6

  • Two hundred and thirty dollars an ounce, about two months of use
  • Six declared fragrance allergens in a serum sold for post-procedure skin
  • Distinctive yeasty culture smell only partly masked by perfume
  • Exosome relaunch changed the label and the price, not the ingredients
  • No hydration in the formula; a moisturiser over it is mandatory
  • Evidence is founder-authored and company-sponsored, with no independent trials
Review

The full review

In 2024 SkinMedica relaunched its oldest product as TNS Recovery Complex Powered by Exosomes, with a trillion of them promised in every bottle, and the ingredient list stayed word for word what it had been: human fibroblast conditioned media, a solubiliser, a gel polymer, a neutraliser, a chelator, glycerin, preservatives and a fragrance. That is not a trick. Exosomes are the small vesicles that living cells shed into their surroundings, packed with proteins and signalling RNA, and fibroblasts cultured for their growth factors have been shedding them into this serum's medium since 1999; the relaunch counted what was already there and put the fashionable word on the label. It is a useful way to understand the product, because TNS Recovery Complex has always been, and remains, a bottle of what cultured human skin cells secrete, and everything it does or does not do follows from that.

The idea began with the brand. Richard Fitzpatrick, a dermatologist who founded SkinMedica in 1999, reasoned that the medium in which bioengineered skin substitutes were grown carried the growth factors that drive wound healing at their natural concentrations, and that applying it to photodamaged faces might trigger some of the same repair. His 2003 pilot study with Rostan in the Journal of Cosmetic and Laser Therapy put a gel of that medium on fourteen patients twice daily for sixty days: eleven improved clinically in at least one area, the periorbital region significantly, optical profilometry showed less surface roughness and shadowing, and punch biopsies found a thirty-seven percent thicker band of new collagen just beneath the epidermis and a twenty-seven percent thicker epidermis. Fourteen patients, no control group and a founder as author make it a pilot rather than proof, and the company-sponsored trials since have been larger but not independent; even so, a biopsy showing new collagen is more than most serums at any price can point to, and it is the reason dermatology practices have dispensed this product for a quarter of a century.

What the medium does on a face, in the experience of nearly five hundred reviewers at one clinical retailer averaging 4.6 stars, is modest and consistent. Skin looks smoother and more even by about four weeks, fine lines soften and the surface firms a little by twelve, and patients coming off a laser or a peel find the redness settles faster, which is the use most practices reach for. It does not hydrate, because there is almost nothing in it to hydrate with; it does not brighten pigment or resurface texture the way an acid or a retinoid does; and its effect plateaus and holds rather than building indefinitely. Long-term users are unusually loyal, and their loyalty is to a subtle, cumulative improvement in the quality of the skin rather than to any dramatic change.

The formula's two faults are old ones. The first is the smell: a conditioned medium is faintly yeasty, and the serum carries that note under a floral fragrance that only partly covers it; users learn to treat the scent as proof the bottle is genuine, since counterfeits are a real problem for a two-hundred-dollar serum. The second is the fragrance itself, which declares six allergens, hydroxycitronellal, linalool, coumarin, alpha-isomethyl ionone, geraniol and isoeugenol, in a product whose main clinical use is on skin that has just been lasered or peeled and whose whole pitch is repair; a minority of users react, and a fragrance-free version would be the obvious improvement a relaunch could have made and did not. The gel is faintly tacky and can pill under a heavy cream applied too soon.

The price is the thing every review eventually reaches. Two hundred and thirty dollars for a one-ounce pump, or a smaller size for a little less, lasting about two months at twice-daily use, puts a year of TNS Recovery north of thirteen hundred dollars, and the exosome relabelling has moved the price up rather than down. What the money buys is the longest record in growth-factor skincare, a founder's biopsy data, a dermatologist's likely endorsement and a subtle, real effect on texture; what it does not buy is independent evidence, a fragrance-free formula, hydration, or anything new since 1999 beyond the word on the label. Growth-factor and exosome serums from newer brands cost half as much with similar evidence, which is to say similarly thin.

For someone whose dermatologist dispenses it after procedures, for a long-term user whose skin has been steadily better on it for years, and for anyone who wants the original of a category rather than a copy and can absorb the cost, TNS Recovery Complex is a serious product with a genuine pedigree. For anyone weighing evidence against dollars, or who reacts to fragrance, or who expected the exosome relaunch to mean a new formula, the honest reading is that this is the same bottle it has been for twenty-seven years, at a price that has learned some new words.

The science

TNS Recovery Complex is human fibroblast conditioned medium, the liquid in which cultured neonatal human dermal fibroblasts have been grown, harvested with the mixture of growth factors, cytokines, soluble collagen, matrix proteins and, in current terminology, exosomes that the cells secrete; SkinMedica lists it as ninety-four percent of the formula. The rationale is that these are the same signalling molecules that coordinate wound healing, and that applying them at physiological concentrations to photodamaged skin might induce a fraction of the same collagen synthesis and epidermal renewal. The founding evidence is Fitzpatrick and Rostan's 2003 pilot study in the Journal of Cosmetic and Laser Therapy, in which fourteen patients applied a gel of the multi-growth-factor medium, then branded Nouricel-MD, to photodamaged facial skin twice daily for sixty days with clinical grading, optical profilometry and 3-millimetre punch biopsies before and after: eleven of fourteen showed clinical improvement in at least one facial area, periorbital improvement was statistically significant, profilometry showed significant reductions in roughness and shadowing consistent with shallower fine lines, and biopsies revealed a thirty-seven percent increase in Grenz-zone collagen thickness and a twenty-seven percent thickening of the epidermis; twelve of fourteen felt their texture had improved. The study's limitations are those of a pilot, small, uncontrolled, and authored by the brand's founder, and the company-sponsored trials that followed, several published in dermatology journals, have reported improvements in wrinkle and texture scores at three months without independent replication.

The mechanistic questions the field has never fully answered apply here. Growth factors are large proteins whose penetration through intact stratum corneum is limited, and the current hypothesis is that they act on epidermal keratinocytes and through follicular routes, signalling downward rather than reaching the dermis directly; exosomes, at tens of nanometres, penetrate more readily and carry protein and microRNA cargo, which is the basis of the 2024 relaunch's emphasis, though the formula's composition is unchanged and no published data isolate an exosome contribution. The remaining six percent of the serum is vehicle: isoceteth-20 solubilises the medium's lipid components, an acrylates crosspolymer neutralised with aminomethyl propanol forms the gel, glycerin provides minimal humectancy, and caprylyl glycol, caprylhydroxamic acid, phenoxyethanol and ethylhexylglycerin preserve a protein-rich medium that would otherwise spoil. The fragrance declares hydroxycitronellal, linalool, coumarin, alpha-isomethyl ionone, geraniol and isoeugenol, six of the regulated fragrance allergens, which is a tolerability compromise in a product positioned for post-procedure use. The serum contains no exfoliant, brightener, humectant of note or antioxidant, so its effect is confined to what the conditioned medium can signal.

References 1 ShowHide
  1. Reversal of photodamage with topical growth factors: a pilot study — Journal of Cosmetic and Laser Therapy (2003)

The clinical view

Growth-factor serums occupy an unusual place in dermatology: they are among the few cosmeceuticals with biopsy data, that data is thin and brand-linked, and the product with the longest record is this one, which many practices have dispensed since the early 2000s and continue to hand patients after lasers, peels and microneedling once the skin has closed. Clinicians who use it tend to describe its effect honestly as a modest, cumulative improvement in texture and fine lines and a faster-settling post-procedure course, and to place it below retinoids and sunscreen in the hierarchy of evidence, with the caveat that a patient who tolerates it and can afford it is unlikely to be harmed and may be helped. The reservations are the fragrance, which draws comment for a post-procedure product and leads some practices to delay it until the skin has fully healed, and the exosome relaunch, which most clinicians regard as marketing applied to an unchanged medium rather than a new formulation. Cost is the recurring conversation, and practices commonly suggest the smaller size or once-daily use for patients who want the product without the full outlay.

Formula

Key ingredients

  1. Human Fibroblast Conditioned Media (TNS) 94%

    The serum is this ingredient: the liquid harvested from cultured human skin fibroblasts, carrying the growth factors, cytokines, matrix proteins and, in the current marketing, exosomes those cells secrete, at ninety-four percent of the formula. It is the original TNS that SkinMedica was founded on, the first cosmetic growth-factor serum, and the reason the product smells and behaves like a cell-culture medium rather than a serum.

    Limited for Aging
  2. Glycerin

    The only humectant in a formula that is otherwise conditioned medium, thickener and preservative, placed low on the list and doing little more than keeping the thin gel from feeling tight as it dries; TNS Recovery is a treatment layer, not a hydrator, and needs a moisturiser over it.

    Plausible mechanism for Dullness
  3. Acrylates/C10-30 Alkyl Acrylate Crosspolymer

    The carbomer-type polymer, neutralised by the aminomethyl propanol beside it, that turns a watery culture medium into a spreadable, faintly tacky gel; it is what makes the serum layerable and is also the reason some users notice pilling under a heavy moisturiser.

    Not yet assessed
  4. Isoceteth-20 (Solubilising Emulsifier)

    A solubiliser, second on the list, that keeps the fragrance and lipid-soluble components of the conditioned medium dispersed in a water-thin base; its high placement, above the thickener, is a reminder of how little else there is in the bottle besides the medium itself.

    Not yet assessed
Full ingredient list 18 ingredients ShowHide

Human Fibroblast Conditioned Media, Isoceteth-20, Ethoxydiglycol, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Aminomethyl Propanol, Disodium EDTA, Ethylhexylglycerin, Glycerin, Caprylyl Glycol, Caprylhydroxamic Acid, Phenoxyethanol, Parfum/Fragrance, Hydroxycitronellal, Linalool, Coumarin, Alpha-Isomethyl Ionone, Geraniol, Isoeugenol

Safety & formulation facts

  • Pregnancy safety unverified
  • Not fragrance free
  • Alcohol free
  • Oil free
  • Silicone free
  • Paraben free
  • Sulfate free
  • Not cruelty free
  • Not vegan
  • Fungal-acne safe
Potential irritants Parfum/FragranceHydroxycitronellalLinaloolCoumarinAlpha-Isomethyl IononeGeraniolIsoeugenol
Common allergens HydroxycitronellalLinaloolCoumarinGeraniolIsoeugenolAlpha-Isomethyl Ionone
Compatibility

Skin types & routine

Routine step serum
Time of day Morning & night
Best season All year
Finish natural, lightweight

Layering

Press a pump over clean, toned skin morning and evening as the first serum, let it set for a minute, and follow with a vitamin C or hydrating serum, moisturiser and, by day, sunscreen; it layers under a retinoid at night without conflict and is the product dermatology practices hand out after lasers and peels once the skin has closed. It contains no hydration to speak of, so a moisturiser over it is not optional.

When to expect results

Skin looks a little smoother and more even within the first four weeks, which is where most users report the first change; fine lines and firmness show measurable improvement at eight to twelve weeks in the company's studies, and the founder's original pilot found new collagen and a thicker epidermis on biopsy at sixty days. Post-procedure redness settles faster in the first week. The effect plateaus and holds with continued use.

Pairs well with vitamin-cretinolhyaluronic-acidniacinamidepeptides

A routine built around it

Morning

  1. Cleanser
  2. SkinMedica TNS Recovery Complexthis product
  3. Vitamin C Serum
  4. Moisturizer
  5. Sunscreen

Night

  1. Cleanser
  2. SkinMedica TNS Recovery Complexthis product
  3. Retinoid
  4. Moisturizer
Guidance

How to use it, and who it's for

How to use

Morning and evening, after cleansing and any toner, dispense one pump into the palm and press it evenly over the face and neck as the first serum, avoiding the eyes; let it set for a minute before layering vitamin C or a hydrating serum, then moisturiser and, in the morning, sunscreen, since the gel has no hydration of its own and can pill if a heavy cream goes on too soon. It can be used under a retinoid at night. After a laser, peel or microneedling, begin only when the practice says the skin has closed, and patch-test first if fragrance has been a problem before. Store away from heat, keep the pump closed, and use within six months of opening; buy from authorised sellers, since counterfeits are common.

Is it worth the price?

Two hundred and thirty dollars for one ounce places TNS Recovery Complex among the most expensive serums in dermatology, and the smaller 0.63-ounce size costs more per millilitre; a pump twice daily empties the bottle in about two months, so a year of use exceeds thirteen hundred dollars. What the money buys is the original growth-factor serum with a founder's biopsy study, a quarter-century of dermatology-office dispensing, an airless pump and a subtle, real effect on texture that its users value; what it does not buy is independent evidence, a fragrance-free formula, hydration, or anything the 2024 exosome relaunch added beyond a word. Growth-factor and exosome serums from newer clinical brands sell for half as much with comparably thin data. For a dermatologist-endorsed post-procedure course or a long-term user whose skin has rewarded it, the value is defensible; on evidence per dollar it is poor.

Who should buy it

Patients of dermatology practices that dispense SkinMedica, particularly around procedures, long-term TNS users whose skin has improved steadily on it, and anyone with normal to dry, non-reactive skin who wants the original growth-factor serum with the longest clinical record and can absorb the price. It suits people who value a subtle, cumulative improvement in texture and fine lines over a dramatic result.

Who should skip it

Fragrance-sensitive, rosacea-prone, eczema-prone or freshly treated skin should wait or choose a fragrance-free growth-factor product, since six declared allergens are on the label. Anyone expecting hydration, brightening or resurfacing from a serum needs different ingredients, anyone weighing independent evidence against cost will find the data thin for the price, and anyone who bought the exosome relaunch expecting a new formula should know the list is unchanged.

Ready to try it?SkinMedica TNS Recovery Complex · $230.00 · 1 fl oz / 30 mL
Details

The product, in detail

Texture
A thin, translucent, faintly amber gel with a slight tackiness as it sets, that spreads in a pump's worth over the face and dries to a barely-there film that moisturiser goes over cleanly if given a minute.
Scent
A light floral-fresh fragrance laid over the faintly yeasty, bread-like smell of the conditioned medium; the culture note is the product's signature and lingers briefly after the perfume fades.
Packaging
A 1 fl oz white airless pump bottle with a rose-gold cap in SkinMedica's current livery, with a 0.63 oz size also sold; the airless pump protects the protein content from air and doses precisely, and the bottle is small for its price.
How long it lasts
About two months at one pump twice daily; three months once daily.
Once opened
Use within 6 months · track your toss-by date →
Size
1 fl oz / 30 mL · other sizes available
Made in
United States
Launched
1999

What the first two weeks feel like

The first application is a thin amber gel with a faint yeasty smell under a floral fragrance, a slight tack as it dries, and nothing much to feel; there is no tingle and no sting unless the fragrance allergens find a reactive face. Skin looks a touch smoother and more even after two or three weeks, and users coming off a laser or peel notice redness settling faster. The smell is the thing to get used to, and long-term users describe it as the sign the bottle is genuine.

The story behind it

Why it exists

Dermatologist Richard Fitzpatrick founded SkinMedica in 1999 around a single idea, that the growth factors bioengineered skin substitutes secreted into their culture medium could be applied to photodamaged faces, and TNS Recovery Complex was the result, with a 2003 pilot study he co-authored showing new collagen and epidermal thickening on biopsy. Allergan acquired the company in 2012, TNS Advanced+ arrived in 2020 as a two-chamber successor, and in 2024 the original was relaunched as TNS Recovery Complex Powered by Exosomes, the same conditioned medium reframed around the vesicles it has always contained, at a price that has climbed with the vocabulary.

About SkinMedica Established Brand (5–20 years)

SkinMedica was founded in 1999 by dermatologist Richard Fitzpatrick around the growth-factor platform in this very serum, and has been owned by Allergan Aesthetics since 2012 with wide distribution through US dermatology practices. TNS Recovery Complex is the product that created the growth-factor category, with a published pilot study from its founder and a series of company-sponsored trials since, and its 2024 relaunch around exosomes rests on brand-held data.

Brand founded 1999 · This product since 1999

Myth vs. reality

What people get wrong about it

MythThe exosomes in the relaunched formula are a new ingredient.

RealityExosomes are extracellular vesicles that fibroblasts secrete into their culture medium along with growth factors and cytokines, so they have been in TNS Recovery Complex since 1999; the 2024 relaunch counted them and put them on the label. The ingredient list is unchanged, and the trillion-exosome claim describes a component of the same human fibroblast conditioned medium the serum has always been.

MythA serum that is ninety-four percent growth-factor medium must be fragrance-free and clinical.

RealityThe remaining six percent includes parfum and six declared fragrance allergens, hydroxycitronellal, linalool, coumarin, alpha-isomethyl ionone, geraniol and isoeugenol, added to mask the medium's yeasty smell; for a serum dispensed to post-procedure and reactive skin that is an odd choice, and it is the reason a minority of users react to a product otherwise built to soothe.

FAQ

Questions people ask

What is in SkinMedica TNS Recovery Complex?

Ninety-four percent human fibroblast conditioned media, the growth factors, cytokines, matrix proteins and exosomes secreted by cultured human skin cells, plus a solubiliser, a gel-forming polymer, glycerin, preservatives and a fragrance carrying six declared allergens; there are no other actives, and the medium is the whole point.

What is the difference between TNS Recovery Complex and TNS Advanced+ Serum?

TNS Recovery Complex is the original 1999 single-phase serum of pure conditioned medium, relaunched in 2024 around its exosome content; TNS Advanced+ is the 2020 two-chamber successor that pairs a next-generation growth factor blend with a second chamber of botanicals and peptides. Advanced+ is the brand's flagship for firmness and sagging, Recovery the purer growth-factor product and the one long-term users often prefer.

Why does SkinMedica TNS Recovery Complex smell strange?

The conditioned medium that makes up most of the serum has a faint yeasty, culture-like smell, and the added floral fragrance only partly masks it; long-term users treat the scent as proof of authenticity, since counterfeits circulate online and often lack it.

Is SkinMedica TNS Recovery Complex safe after a laser or chemical peel?

Dermatology practices commonly dispense it once treated skin has closed, because the growth-factor medium is thought to support repair and users report faster settling of redness; the caveat is the fragrance, which carries six declared allergens and can sting freshly treated or reactive skin, so timing should follow the practice's advice.

How long does TNS Recovery Complex take to show results?

Users typically report smoother, more even skin by four weeks, and the company's studies place measurable improvement in fine lines and texture at eight to twelve weeks; the founder's original pilot found new collagen and epidermal thickening on biopsy after sixty days of twice-daily use. Results are maintained with continued use.

Is SkinMedica TNS Recovery Complex worth 230 dollars?

It is the growth-factor serum with the longest record and a founder's biopsy study behind it, and its users are unusually loyal, but the effect on lines and texture is modest, the exosome relaunch adds vocabulary rather than ingredients, and the price is among the highest in dermatology; it is worth it to a committed user with a dermatologist's endorsement and hard to justify on evidence per dollar.

Reviews

What shoppers tend to say

Recurring themes our editors read across retailer reviews — summaries in our words, not quotations, and not a substitute for a patch test.

Common praise

  • Smoother, plumper skin within a month
  • Fine lines and texture visibly better by twelve weeks
  • Speeds recovery after lasers and peels
  • A little goes a long way from the pump
  • Decades of steady results for long-term users

Common complaints

  • Two hundred and thirty dollars an ounce
  • Distinctive yeasty smell only partly masked by fragrance
  • Six fragrance allergens in a post-procedure serum
  • Tacky gel that can pill under moisturiser
  • Counterfeits circulating online
Next stepCheck it against what you already useClashes, spacing and the right order, with everything on your shelf.